Press Releases MaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD Independent Data Safety Monitoring Board (DSMB) recommends to continue HERACLES study without modification. Lyon, France,…nboutaouiFebruary 5, 2019
Press Releases MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients at the ASH 2018 Annual Meeting Data show achievement of primary endpoint, demonstration of functional microbiota restoration, inflammation reduction and positive…nboutaouiDecember 2, 2018
Press Releases MaaT Pharma to Present Positive Results from Phase 1b/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting Lyon, France, November 2, 2018 – MaaT Pharma announced today that the company will present…MaaT PharmaNovember 6, 2018
Press Releases MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD Microbiome restoration biological drug product to be tested for safety and overall survival impact in…MaaT PharmaOctober 12, 2018
Press Releases MaaT Pharma Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale…MaaT PharmaSeptember 18, 2018
Press Releases MaaT Pharma and Lutech Sign Licensing Agreement for Graft-vs-Host Disease MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of…MaaT PharmaJune 21, 2018
Press Releases Dr. Joël Doré, MaaT Pharma’s co-founder, received awards for his work Dr. Joël Doré, MaaT Pharma’s co-founder, received awards for his work Created in the…MaaT PharmaMay 18, 2018
Press Releases MaaT Pharma Launches European Clinical Trial in Acute Graft-versus-Host Disease MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase…MaaT PharmaMarch 5, 2018
Press Releases MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer…MaaT PharmaNovember 30, 2017
Press Releases MaaT Pharma completes patient recruitment of its clinical trial Maat Pharma has reached the target number of patients to be treated in its first…MaaT PharmaJuly 20, 2017